---
title: "GLUT10 (SLC2A10) Expression in Breast Cancer and Its Role in Cisplatin Resistance"
id: "pubmed-42595549"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42595549"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42595549/"
doi: "10.3760/cma.j.cn112152-20251018-00521"
published_at: "2026-08-23T00:00:00.000Z"
evidence_level: "English Abstract"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLUT10 (SLC2A10) Expression in Breast Cancer and Its Role in Cisplatin Resistance
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42595549
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42595549/)
- **DOI:** [10.3760/cma.j.cn112152-20251018-00521](https://doi.org/10.3760%2Fcma.j.cn112152-20251018-00521)
- **Published At:** 2026-08-23T00:00:00.000Z
- **Evidence Rating:** English Abstract
## Executive GIST (TL;DR)
- This study analyzed **GLUT10** (encoded by **SLC2A10**) expression across cancers using TCGA/GTEx via GEPIA2 and compared breast cancer versus normal breast tissue using UALCAN. - UALCAN showed **SLC2A10** mRNA levels were 1.85-fold higher in breast cancer than in normal breast tissue (P < 0.001). - RT-qPCR across breast cancer cell lines found SLC2A10 mRNA highest in Hs578T, then SK-BR-3, MDA-MB-468, T-47D, and MCF7; all were significantly higher than normal breast epithelial cells (P < 0.001). - In SK-BR-3 cells, knockdown of SLC2A10 (shSLC2A10#1 and #2) increased intracellular **ROS** (relative fluorescence intensities 1.78±0.12 and 2.05±0.15) and increased sensitivity to **cisplatin**, reduced colony formation, and promoted cisplatin-induced ROS accumulation and apoptosis compared with shScr control (P < 0.05 where reported). - In MDA-MB-231 cells, SLC2A10 overexpression decreased intracellular ROS (relative fluorescence intensity 0.58±0.09, P < 0.05), reduced cisplatin sensitivity, and inhibited cisplatin-induced ROS accumulation and apoptosis versus vector control. - Western blotting measured GLUT10 and cleaved caspase-3; RT-qPCR measured SLC2A10 mRNA; CM-H2DCFDA probe measured ROS; drug sensitivity, colony formation, and flow cytometry assessed cisplatin response and apoptosis. - Overall conclusion: **GLUT10 is highly expressed in breast cancer** and appears to mediate **cisplatin resistance** via regulation of intracellular **ROS**, suggesting SLC2A10/GLUT10 as a potential therapeutic target to reverse drug resistance in breast cancer. - Conflict of interest: all authors declared no conflicts.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42595549/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42595549%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42595549/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42595549/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42595549/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42595549/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42595549/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42595549/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42595549%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42595549%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42595549/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42595549/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42595549/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42595549/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Chinese Medical Association Publishing House Ltd. full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.medjournals.cn-CMAPH-Linkout-logo.png) Chinese Medical Association Publishing House Ltd. ](https://www.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.cn112152-20251018-00521 "See full text options at Chinese Medical Association Publishing House Ltd.") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42595549/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42595549/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42595549/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42595549/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42595549/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42595549/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42595549/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42595549/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42595549/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42595549/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42595549/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42595549/#linkout) Title & authors Abstract Conflict of interest statement Similar articles Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Zhonghua Zhong Liu Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Zhong+Liu+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Zhong+Liu+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42595549/) . 2026 Aug 23;48(8):954-962. doi: 10.3760/cma.j.cn112152-20251018-00521. # [Expression characteristics of GLUT10 in breast cancer and its mechanism in mediating cisplatin resistance] [Article in Chinese] [Y F Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+YF&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Y L Cai](https://pubmed.ncbi.nlm.nih.gov/?term=Cai+YL&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [T X Yi](https://pubmed.ncbi.nlm.nih.gov/?term=Yi+TX&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J L Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+JL&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Z A Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+ZA&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Y X Qi](https://pubmed.ncbi.nlm.nih.gov/?term=Qi+YX&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J Z Jin](https://pubmed.ncbi.nlm.nih.gov/?term=Jin+JZ&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+J&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Q Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+Q&cauthor_id=42595549)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-2 "Zhejiang University Shaoxing Research Institute, Life Sciences Branch Center, Shaoxing 312000, China."), [H Hu](https://pubmed.ncbi.nlm.nih.gov/?term=Hu+H&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#full-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China.") Affiliations Expand ### Affiliations * 1 School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China. * 2 Zhejiang University Shaoxing Research Institute, Life Sciences Branch Center, Shaoxing 312000, China. * PMID: **42595549** * DOI: [ 10.3760/cma.j.cn112152-20251018-00521 ](https://doi.org/10.3760/cma.j.cn112152-20251018-00521) Item in Clipboard # [Expression characteristics of GLUT10 in breast cancer and its mechanism in mediating cisplatin resistance] [Article in Chinese] Y F Wang et al. Zhonghua Zhong Liu Za Zhi. 2026. Show details Display options Display options Format Abstract PubMed PMID Zhonghua Zhong Liu Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Zhong+Liu+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Zhong+Liu+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42595549/) . 2026 Aug 23;48(8):954-962. doi: 10.3760/cma.j.cn112152-20251018-00521. ### Authors [Y F Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+YF&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Y L Cai](https://pubmed.ncbi.nlm.nih.gov/?term=Cai+YL&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [T X Yi](https://pubmed.ncbi.nlm.nih.gov/?term=Yi+TX&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J L Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+JL&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Z A Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+ZA&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Y X Qi](https://pubmed.ncbi.nlm.nih.gov/?term=Qi+YX&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J Z Jin](https://pubmed.ncbi.nlm.nih.gov/?term=Jin+JZ&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [J Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+J&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China."), [Q Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+Q&cauthor_id=42595549)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-2 "Zhejiang University Shaoxing Research Institute, Life Sciences Branch Center, Shaoxing 312000, China."), [H Hu](https://pubmed.ncbi.nlm.nih.gov/?term=Hu+H&cauthor_id=42595549)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42595549/#short-view-affiliation-1 "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China.") ### Affiliations * 1 School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053,China. * 2 Zhejiang University Shaoxing Research Institute, Life Sciences Branch Center, Shaoxing 312000, China. * PMID: **42595549** * DOI: [ 10.3760/cma.j.cn112152-20251018-00521 ](https://doi.org/10.3760/cma.j.cn112152-20251018-00521) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract in [ English, ](https://pubmed.ncbi.nlm.nih.gov/42595549/#eng-abstract) [ Chinese ](https://pubmed.ncbi.nlm.nih.gov/42595549/#zho-abstract) **Objective:** This study aims to investigate the expression characteristics of GLUT10 in breast cancer and its role in mediating cisplatin resistance, with the goal of providing a new molecular target for personalized breast cancer treatment. **Methods:** Data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases were analyzed using the GEPIA2 platform to assess pan-cancer expression, while the UALCAN platform was used to analyze expression differences between breast cancer and normal breast tissues. _In vitro_ , SK-BR-3 cells were divided into three groups: shScr (transfected with non-targeting scrambled shRNA), shSLC2A10#1, and shSLC2A10#2. MDA-MB-231 cells were divided into a vector control group and an SLC2A10 overexpression group. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect _SLC2A10_ mRNA expression. Western blotting was used to detect GLUT10 and cleaved caspase-3 protein expression. The CM-H2DCFDA probe was used to measure intracellular reactive oxygen species (ROS) levels. Drug sensitivity and colony formation assays were performed to evaluate cisplatin sensitivity, and flow cytometry was used to detect apoptosis rates. **Results:** GEPIA2 analysis showed that GLUT10 expression was downregulated in adrenocortical carcinoma, cervical squamous cell carcinoma and adenocarcinoma, and kidney chromophobe tumor tissues compared to normal tissues, whereas it was upregulated in invasive breast cancer, glioma, skin melanoma, and thymoma. UALCAN analysis revealed that SLC2A10 mRNA levels in breast cancer tissues were 1.85-fold higher than in normal breast tissues (_P_ ＜0.001). RT-qPCR results showed that SLC2A10 mRNA expression levels in breast cancer cell lines, ranked from high to low, were Hs 578T (160.5±12.3), SK-BR-3 (115.2±10.5), MDA-MB-468 (50.1±5.2), T-47D (35.4±4.1), and MCF7 (25.6±3.8), all significantly higher than in normal breast epithelial cells (_P_ ＜0.001). In SK-BR-3 cells, compared with the shScr group, the shSLC2A10#1 and shSLC2A10#2 groups exhibited increased intracellular ROS levels (relative fluorescence intensity: 1.78±0.12 and 2.05±0.15, respectively; _P_ ＜0.05), increased cisplatin sensitivity, reduced colony numbers, and promoted cisplatin-induced ROS accumulation and apoptosis. In MDA-MB-231 cells, compared with the vector control group, the SLC2A10 overexpression group showed decreased intracellular ROS levels (relative fluorescence intensity: 0.58±0.09, _P_ ＜0.05), decreased cisplatin sensitivity, and inhibited cisplatin-induced ROS accumulation and apoptosis. **Conclusion:** GLUT10 is highly expressed in breast cancer and mediates cisplatin resistance by regulating ROS levels, suggesting it may serve as a novel therapeutic target for reversing drug resistance in breast cancer. **目的：** 探讨由溶质载体家族2成员10（SLC2A10）基因编码的葡萄糖转运蛋白10（GLUT10）在乳腺癌中的表达特征，及其在顺铂耐药中的作用机制，为乳腺癌的个体化治疗提供新的分子靶点。 **方法：** （1）利用癌症基因组图谱（TCGA）和基因型-组织表达（GTEx）数据库资料，通过GEPIA2平台分析GLUT10泛癌表达情况，通过UALCAN平台分析GLUT10在乳腺癌组织与正常乳腺组织中的表达差异。（2）将乳腺癌SK-BR-3细胞设shScr组（转染非靶向乱序shRNA）、shSLC2A10#1组和shSLC2A10#2组，将MDA-MB-231细胞设空载体组和SLC2A10过表达组（转染SLC2A10全长过表达载体），采用反转录定量聚合酶链反应（RT-qPCR）检测细胞中SLC2A10 mRNA的表达，采用蛋白质免疫印迹法检测细胞中GLUT10蛋白和活化型caspase-3的表达，采用5-（和-6）-氯甲基-2′，7′-二氯二氢荧光素二乙酸酯探针检测细胞中活性氧（ROS）水平，采用药物敏感性实验和克隆形成实验观察细胞对顺铂的敏感性，采用流式细胞术检测细胞凋亡率。 **结果：** GEPIA2分析显示，GLUT10在肾上腺皮质癌、宫颈鳞状细胞癌和腺癌、肾嫌色细胞癌肿瘤组织中的表达水平低于相应正常组织，而在浸润性乳腺癌、胶质细胞瘤、皮肤黑色素瘤和胸腺瘤肿瘤组织中的表达水平高于相应正常组织。UALCAN分析显示，乳腺癌组织中SLC2A10 mRNA水平较正常乳腺组织升高1.85倍（ _P_ ＜0.001）。RT-qPCR检测结果显示，乳腺癌细胞中SLC2A10 mRNA的表达水平从高到低依次为Hs 578T细胞（160.5±12.3）、SK-BR-3细胞（115.2±10.5）、MDA-MB-468细胞（50.1±5.2）、T-47D细胞（35.4±4.1）及MCF7细胞（25.6±3.8），均高于正常乳腺上皮细胞（均 _P_ ＜0.001）。在SK-BR-3细胞中，与shScr组比较，shSLC2A10#1组和shSLC2A10#2组细胞内ROS水平升高（相对荧光强度分别为1.78±0.12和2.05±0.15，均 _P_ ＜0.05），对顺铂的敏感性增高，集落数减少，促进顺铂诱导的ROS水平增加和细胞凋亡。在MDA-MB-231细胞中，与空载体组比较，SLC2A10过表达组的细胞内ROS水平降低（相对荧光强度为0.58±0.09， _P_ ＜0.05），对顺铂的敏感性降低，抑制顺铂引起的ROS水平增加和细胞凋亡。 **结论：** GLUT10在乳腺癌中高表达，通过调节乳腺癌细胞内ROS水平介导顺铂耐药，可能成为逆转乳腺癌耐药的新治疗靶点。. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement 所有作者声明无利益冲突 ## Similar articles * [ [MiR-1-3p inhibits mitophagy in esophageal squamous cell carcinoma by targeting SLC7A11]. ](https://pubmed.ncbi.nlm.nih.gov/40692251/) Zhen SM, Zhang HR, Si JX, Wang JQ, Zhao Y, Jia YL, Liu LH.Zhen SM, et al.Zhonghua Zhong Liu Za Zhi. 2025 Jul 23;47(7):645-656. doi: 10.3760/cma.j.cn112152-20240219-00078.Zhonghua Zhong Liu Za Zhi. 2025.PMID: 40692251Chinese. * [ Blocking of SIRT7/FOXO3a axis by miR-152-3p enhances cisplatin sensitivity in breast cancer. ](https://pubmed.ncbi.nlm.nih.gov/39241827/) Shi X, Ji Y, Wu X, Du Y, Yan X, Wang Y, Xia X.Shi X, et al.Am J Med Sci. 2025 Jan;369(1):105-115. doi: 10.1016/j.amjms.2024.08.028. Epub 2024 Sep 4.Am J Med Sci. 2025.PMID: 39241827 * [ [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing _CCAT_ 2]. ](https://pubmed.ncbi.nlm.nih.gov/32543135/) He L, Du ZD, Wang Y, Meng RQ, Zhao WW.He L, et al.Sichuan Da Xue Xue Bao Yi Xue Ban. 2020 May;51(3):312-319. doi: 10.12182/20200560601.Sichuan Da Xue Xue Bao Yi Xue Ban. 2020.PMID: 32543135Chinese. * [ Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1. ](https://pubmed.ncbi.nlm.nih.gov/23430586/) Liu H, Wang Y, Li X, Zhang YJ, Li J, Zheng YQ, Liu M, Song X, Li XR.Liu H, et al.Tumour Biol. 2013 Jun;34(3):1713-22. doi: 10.1007/s13277-013-0708-0. Epub 2013 Feb 22.Tumour Biol. 2013.PMID: 23430586 * [ RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation. ](https://pubmed.ncbi.nlm.nih.gov/24909514/) Lu C, Zhou LY, Xu HJ, Chen XY, Tong ZS, Liu XD, Jia YS, Chen Y.Lu C, et al.Acta Pharmacol Sin. 2014 Jul;35(7):929-36. doi: 10.1038/aps.2014.31. Epub 2014 Jun 9.Acta Pharmacol Sin. 2014.PMID: 24909514Free PMC article. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42595549) ## Publication types * English Abstract Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22English+Abstract%22%5Bpt%5D&sort=
## Related Clinical Research

- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Choroidal metastasis: Age and metastatic burden predict survival in a single-center cohort](https://medichelpline.com/clinical-feed/plos-one-12-choroidal-metastasis-impact-of-primary-tumors-and-age-on-survival-a-single.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [SLFN11 as a biomarker of cisplatin sensitivity in pediatric solid tumors](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-slfn11-enhances-cisplatin-sensitivity-in-pediatric-cancer-via-activation-of.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.